← FDA DRUG APPROVALS

FDA ANDA · ANDA078830

SCOPOLAMINE TRANSDERMAL SYSTEM

Sponsor: PADAGIS US

APPLICATION
ANDA078830
TYPE
ANDA
ORIGINAL APPROVAL
2015-01-30
LATEST ACTION
2026-02-09
ROUTE
TRANSDERMAL
DOSAGE FORM
SYSTEM
MARKETING STATUS
Prescription

Products

SCOPOLAMINEPrescription
SCOPOLAMINE 1MG/72HR · SYSTEM · TRANSDERMAL

Approval history

2026-02-09Labeling · Supplement 21 · standardAP
2026-02-09Labeling · Supplement 16 · standardAP
2023-10-27Labeling · Supplement 11 · standardAP
2015-01-30OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →